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Abstract
Serine proteases in the nervous system have functional
roles in neural plasticity. Among them, urokinase-type
plasminogen activator (uPA) exerts a variety of functions
during development, and is involved in learning and mem-
ory. Furthermore, psychostimulants strongly induce uPA
expression in the mesolimbic dopaminergic pathway. In this
study, doxycycline-regulatable lentiviruses expressing either
uPA, a dominant-negative form of uPA, or non-regulatable
lentiviruses expressing small interfering RNAs (siRNAs)
targeted against uPA have been prepared and injected into
the ventral tegmental area (VTA) of rat brains. Over-
expression of uPA in the VTA induces doxycycline-
dependent expression of its receptor, uPAR, but not its
inhibitor, plasminogen activator inhibitor-1 (PAI-1). uPAR
expression in the VTA is repressed upon silencing of uPA
with lentiviruses expressing siRNAs. In addition, over-
expression of uPA in the VTA promotes a 15-fold increase
in locomotion activity upon cocaine delivery. Animals
expressing the dominant-negative form of uPA did not dis-
play such hyperlocomotor activity. These cocaine-induced
behavioural changes, associated with uPA expression, could
be suppressed in the presence of doxycycline or uPA-spe-
ciﬁc siRNAs expressing lentiviruses. These data strongly
support the major role of urokinase in cocaine-mediated
plasticity changes.
Keywords: addiction, in vivo gene transfer, lentivirus,
plasticity, small interfering RNA, urokinase-type plasminogen
activator.
Proteolytic enzymes play a role in normal and pathological
events in the brain, including plasticity. Plasminogen activa-
tors are important mediators of extracellular metabolism,
involved in remodelling events during development and
regeneration in the nervous system. The generation of
plasmin from its inactive precursor plasminogen is mediated
by serine enzymes known as tissue-type plasminogen
activator (tPA) and urokinase-type plasminogen activator
(uPA), and contributes to the turnover of the extracellular
matrix in the central nervous system. tPA plays a role in
cognitive memory, mediates reverse occlusion plasticity of
the visual cortex, and promotes neurodegeneration. tPA is
synthesized by neurons of most brain regions, in particular
within the hippocampus and hypothalamus (Sappino et al.
1993). tPA-catalyzed proteolysis in neural tissues is not
limited to ontogeny, but may also contribute to adult central
nervous system physiology, for instance by inﬂuencing
neuronal plasticity and synaptic reorganization (Sappino
et al. 1993; Nakagami et al. 2000). The identiﬁcation of an
extracellular proteolytic system active in the adult central
nervous system may also help gain insights into the
pathogeny of neurodegenerative disorders associated with
extracellular protein deposition.
Alternatively, the uPA is an inducible secreted serine
protease traditionally linked to blood clot dissolution and
initiates an extracellular proteolytic cascade implicated in a
broad spectrum of events related to cell adhesion and tissue
remodelling, but its function in the brain is poorly under-
stood. Transgenic mice producing high levels of uPA
speciﬁcally in nerve cells in the brain showed uPA involve-
ment in learning-related plasticity, but these mice were
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impaired in tasks of spatial, olfactory and taste-aversion
learning while displaying normal sensory and motor capa-
bilities (Meiri et al. 1994). Furthermore, in the normal mouse
brain, treatment with the seizure-inducing agents kainic acid
and metrazol activated the uPA gene in the hippocampus and
amygdala (Sharon et al. 2002; Miskin and Abramovitz
2005). The gene encoding the speciﬁc inhibitor of uPA,
PAI-1, was also strongly activated. The genes of uPA and
PAI-1 thus respond to neuronal triggering similarly to
plasticity-related genes (Dent et al. 1993; Yoshida and
Shiosaka 1999; Nakagami et al. 2000; Miskin et al. 2005).
Induction of uPA receptor (uPAR) promotes cell adhesion
through its interaction with vitronectin in the extracellular
matrix, and facilitates cell migration and invasion by
localizing uPA to the cell surface, the balance between cell
adhesion and cell detachment being governed by PAI-1 (Yu
et al. 2001; Deng et al. 2003).
Thus, expression of uPA and its receptor, uPAR, may
play an important role in synaptogenesis, remodelling, and
reactive processes other than for cell migration in develop-
ing mouse brain (Del Bigio et al. 1999). Therefore, its
expression is a major determinant of the basal level of
activated ERK/MAP kinase (Zhong et al. 2001), a process
that may inhibit apoptosis during development. Further-
more, uPA, under the control of uPAR, is responsible for
activating hepatocyte growth factor, which plays an
important role during development for the movement of
nerve cells to their correct location in the brain network
(Powell et al. 2001). Mice lacking uPAR have an increased
susceptibility to seizure, an altered electroencephalogram
‘EEG’ proﬁle, increased anxiety-like behaviour and signi-
ﬁcant loss of social interaction, many features which are
shared with individuals with autism (Powell et al. 2001).
Therefore, uPA appears to be involved in complex brain
functions and to play a major role in learning-related
plasticity (Miskin et al. 1990; Masos and Miskin 1996; Yu
et al. 2001).
In previous studies, we have shown that uPA is strongly
induced upon psychostimulant delivery. Cocaine induced 2–
6-fold increase of uPA mRNA in the mesolimbic dopamin-
ergic pathway, including the ventral tegmental area (VTA),
the nucleus accumbens (Nac) and the hippocampus (Bahi
et al. 2004a). Furthermore, local over-expression of uPA in
these brain area, by stereotaxic injection of a doxycycline-
regulated uPA-expressing lentivirus, showed a 12-fold
increase in locomotor activity after cocaine treatment com-
pared with saline injection, an effect completely abolished
with doxycycline or when a dominant-negative form of uPA
had been delivered (Bahi et al. 2004a). In order to further
clarify the role of uPA in psychostimulant-induced beha-
viour, lentiviruses expressing small interfering RNAs
(siRNAs) targeted against uPA mRNA have been prepared
and tested both in vitro and in vivo. Our data clearly establish
that uPA induces strong behavioural changes associated with
drug delivery. The physiological function of these observa-
tions is discussed.
Experimental procedures
Lentiviral vectors
Design of uPA-speciﬁc siRNA followed published guidelines (Bahi
et al. 2005a,b) and was performed using the Internet application of
Hannon’s design criterion http://katahdin.cshl.org:9331/RNAi/html/
rnai.html; uPA-Sil1: 21–45; uPA-Sil2: 1270–1293 and uPA-Sil3:
673–692. In order to minimize off-target effects, a BLAST homo-
logy search (based on sense and antisense sequences) was systema-
tically performed to be sure that a single mRNA sequence was
targeted.
Brieﬂy, an XhoI restriction site was 3¢ added to each oligo. Using
the pSilencer 1.0-U6 (Ambion, Austin, TX, USA) as a template and
a U6 promoter-speciﬁc forward primer containing the BamHI
restriction site, each target was added to the mouse U6 promoter by
PCR. The PCR product was digested with BamHI and XhoI, cloned
into similar sites in pTK431 and sequenced to verify the integrity of
each construct (Bahi et al. 2005a,b).
Lentivirus construction of Lenti-uPA and Lenti-GFP
Brieﬂy, the rat uPA cDNA was ampliﬁed by reverse transcription
using Superscript II Reverse Transcriptase (Invitrogen, Carlsbad,
CA, USA) following the manufacturer’s instructions. The cDNA
was then PCR ampliﬁed, 6His-tagged, digested with BamHI and
XhoI and cloned into similar sites in pTK431 (Bahi et al. 2004a).
A control vector construct, pTK433 in which green ﬂuorescent
protein (GFP) expression is regulated by a tetracycline inducible
promoter, was generated by cloning a BamHI/BglII DNA fragment
containing the GFP gene into a BamHI site in pTK431 (Bahi et al.
2004a,b; 2005a,b).
The mutated form of uPA used in this study was described
previously (Bahi et al. 2004a). Brieﬂy, the uPA cDNA sequence was
point-mutated in two active site-composing amino acids, H225G
and S377A using the QuickChange site-directed mutagenesis kit
according to the manufacturer’s instructions (Stratagene, La Jolla,
CA, USA). PCRs were performed with wild-type pCRII-uPA-His6
cDNA as template. The PCR product was then digested with
BamHI/XhoI and cloned into pTK431 transfer vector. cDNA inserts
of the mutant were sequenced to ensure that the correct mutations
were introduced. All plasmids were CsCl2 puriﬁed.
Vesicular stomatitis virus G pseudotyped lentiviruses were
produced by the transient calcium phosphate co-transfection of
human embryonic kidney (HEK)293T cells with pTK vectors,
together with pMDG-VSV-G and pDNRF as previously described
(Naldini et al. 1996; Bahi et al. 2004a,b; 2005a,b). Lentiviral vector
quantiﬁcations were performed according to the p24 ELISA (KPL,
Gaithersburg, MA, USA) in accordance with the manufacturer’s
instructions.
Cell culture
HEK293T cells were maintained under standard conditions in
Dulbecco’s modiﬁed Eagle’s medium supplemented with 10% fetal
bovine serum and 2 mM L-glutamine. For infections, 105 293T cells
were plated, 24 h later lentiviruses were mixed with 8 lg/mL
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Polybrene (Sigma, St Louis, MO, USA), added to the cells and
incubated at 37C.
For doxycycline regulation, brieﬂy HEK293T cells were infected
with 3, 6 or 9 lL from viral stock of Lenti-uPA or Lenti-uPA-Mut,
together with 3 lL of Lenti-CD81 (Bahi et al. 2004b; 2005b).
Culture medium was supplemented with 30 ng/mL of doxycycline.
To test the knock-down effect of uPA with Lenti-uPA-siRNAs
in vitro, control cells were infected with 3 lL of Lenti-uPA, together
with 3 lL of Lenti-CD81, knock-down was performed by adding
either 3 lL of Lenti-uPA-Sil1, 3 lL of Lenti-uPA-Sil2, 3 lL of
Lenti-uPA-Sil3 or 3 lL of the three targets together.
For all infections, after 48 h medium was changed (with or
without 30 ng/mL doxycycline) and cells were kept in culture for a
further 48 h. Cells were than processed for total RNA extraction
(Bahi et al. 2005a).
Quantitative RT-PCR
To analyse uPA mRNA levels, total RNA was extracted from
HEK293T cells and the VTA region of brains stereotaxically
injected with lentiviral vectors using Trizol reagent (Invitrogen)
according to the manufacturer’s instructions. Retrotranscription step
was performed using Superscript II Reverse Transcriptase (Invitro-
gen) following the manufacturer’s instructions. Real-time quantita-
tive PCR was performed using the iCycler with an IQ SYBR Green
Supermix (Bio-Rad Laboratories, Hercules, CA, USA) for DNA
detection. Expression levels of the housekeeping gene encoding
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were also
quantiﬁed and used for normalization. Primers for rat uPA were 5¢-
CAGATCCGATGCTCTTAGCC-3¢ and 5¢-TAGAGCCTTCTGGC-
CACACT-3¢. Primers for rat uPA receptor (uPA-R): 5¢-GCTGC-
AACTTCACCCAATGC-3¢ and 5¢-ACTCCGGTTTCCCAGCA-
CAT-3¢. Primers for rat uPA inhibitor (uPA-I): 5¢-TTCCTTGAATG-
TGCCAATGA-3¢ and 5¢-GTTTTCCACCGTCCTTTGAA-3¢. Prim-
ers for rat CD81 were 5¢-TGATCCTGTTTGCCTGTGAG-3¢ and 5¢-
CAGTTGAGCGTCTCATGGAA-3¢. Primers for GAPDH were 5¢-
ATGACTCTACCCACGGCAAG-3¢ and 5¢-CATACTCAGCACC-
AGCATCAC-3¢. Primers for b-actin were 5¢-AGCCATGTACGTA-
GCCATCC-3¢ and 5¢-CTCTCAGCTGTGGTGGTGAA-3¢. All
primers were designed using PRIMER3 software (Bahi et al.
2004a,b; 2005a,b). The 199-base pair fragment for rat uPA was
ampliﬁed using the following PCR conditions: 3 min at 95C (initial
denaturation), a 20C/s temperature transition rate up to 95C for
30 s and 64C for 30 s, repeated 40 cycles (ampliﬁcation). The PCR
reaction was evaluated by melting curve analysis following the
manufacturer’s instructions and checking the PCR products on 2%
agarose gel.
Animal work
Animals used in this experiment were male Wistar rats weighing
225–250 g (BRL, Fu¨llinsdorf, Switzerland). All animal experiments
were carried out in accordance with the guidelines and regulations
for Animal Experimentation, BAG, Bern, Switzerland. The animals
were housed in threes in clear plastic cages with wire grid lids.
Access to food and water was unrestricted. The animals were kept in
the animal facility maintained on a 12-h light : 12-h dark cycle
(lights off at 07.00 h).
At the end of the behavioural tests, rats were decapitated and
brains were quickly removed. Various regions including the VTA
were rapidly dissected out, frozen in Trizol reagent and stored in a
freezer at )80C until assayed.
Surgery
All surgical procedures were performed as previously described
(Bahi et al. 2004a,b; 2005a,b). Brieﬂy, rats were anaesthetized
with a mix of ketamine/xylazine (100 mg/kg/10 mg/kg, i.p.).
Using a 5-lL Hamilton syringe, 4 lL of concentrated lentiviral
solutions mix (c.a. 200 000 ng of p24 antigen/mL) per site were
bilaterally injected into the VTA, at the corresponding coordinates
(anterior )6; lateral ± 0.6; ventral )8; Paxinos and Watson 1998),
with a rate of 1 lL/min, in a stereotaxic frame. The needle was
then left in place for an additional 5 min and gently withdrawn.
After surgery, animals were injected subcutaneously with a single
dose of caprofen (5 mg/kg) to limit inﬂammatory reaction
resulting from the surgery and 5 mL of pre-warmed saline
to avoid animal dehydration. Animals were left 7 days for
recovery.
Measurement of locomotor activity
This test was performed as previously described (Bahi et al.
2004a,b; 2005a,b). Brieﬂy, after surgery animals were left for
recovery for 7 days, and then chronically injected with cocaine
(15 mg/kg i.p.) over 15 days. Chronic cocaine administration was
subdivided into three 5-day sessions.
Session A, without doxycycline
Initially, animals (n ¼ 9) were daily injected over 5 days under a
normal regimen, with saline (1 mL/kg, i.p.), placed individually in
MED-OFA-RS cage (MED Associates Inc., Georgia, VT, USA) and
locomotor activity was measured every 5 min for baseline. After
30 min, the session automatically paused and, during this interval,
each rat received an intraperitoneal injection of cocaine-HCl
(15 mg/kg) and was then placed back into the locomotor activity-
monitoring cage for 60 min. At the end of session A, three rats were
killed for RNA extraction.
Session B, with doxycycline
Over the next ﬁve consecutive days, remaining animals (n ¼ 6)
were given water supplemented with 0.02% doxycycline and 5%
sucrose (Sigma) and tested for locomotor activity every day with
daily cocaine administration as in session A. At the end of
session B, three animals were killed.
Session C, without doxycycline
The remaining animals (n ¼ 3) were then fed doxycycline-free
water over 5 days with daily monitoring for locomotor activity with
daily cocaine administration as in session A, and ﬁnally killed at the
end of this last session.
After death, brains were dissected out (including the VTA) and
used for total RNA extraction. After reverse transcription, mRNA
expression levels were measured by means of quantitative real time-
PCR.
To test uPA-induced locomotor activity upon cocaine delivery,
B428, a speciﬁc uPA inhibitor (Towle et al. 1993; Evans and Sloan-
Stakleff 2000; Todaro et al. 2003) was used. A group of animals
was bilaterally injected into the VTA with Lenti-uPA using a
stereotaxic frame as previously described. After recovery, rats were
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injected with B428 (30 mg/kg, i.p.). Thirty minutes later rats were
injected with saline (1 mL/kg, i.p.) and placed in open-ﬁeld cages
for the habituation phase. After this period, animals received cocaine
(15 mg/kg) and then were placed back into the locomotor activity-
monitoring cage for 60 min.
Statistical analysis
All data were expressed as the means ± SE. The statistical
evaluation was performed as previously described (Bahi et al.
2004a,b; 2005a,b).
Immunohistochemistry
Immunohistochemistry was performed according to previously
published procedures (Bahi et al. 2004a).
Results
Lentivirus-mediated uPA expression in vitro in
HEK293T cells
For this study, lentiviruses expressing either uPA, a domin-
ant-negative form of uPA (uPA-mut), or siRNAs targeted
against uPA have been prepared and tested in vitro.
HEK293T cells were infected with various amounts of
Lenti-uPA or Lenti-uPA-Mut, together with Lenti-CD81
(used as a control, see Bahi et al. 2004a) and expression was
quantiﬁed by means of quantitative RT-PCR, normalized
against GAPDH. As shown in Fig. 1, expression of uPA by
Lenti-uPA or its mutated form Lenti-uPA-Mut are titre-
dependent. Increases (2.7-, 5.6- and 10.7-fold) were
observed with 3, 6 or 9 lL viral stock in cells infected with
Lenti-uPA (Fig. 1a), whereas cells infected with Lenti-uPA-
Mut displayed a 3.2-, 6.0- and 12.0-fold increase,
respectively, at equivalent titres (Fig. 1c). Under these
conditions, Lenti-CD81 also induced the expression of
CD81 transcripts (3-fold increase), but its transcript level
was not affected by Lenti-uPA or Lenti-uPA-Mut titre
changes. Endogenous b-actin mRNA was not affected under
these conditions and a constant ratio of2.6 to 2.8 was found
under all conditions. This expression of uPA, uPA-Mut and
CD81 is regulated by low doses of doxycycline (30 ng/mL).
Lenti-uPA-mediated uPA transcript expression was com-
pletely abolished at low virus concentrations (Fig. 1b) and
uPA expression reached almost basal levels (ratio 1.3),
similar to levels observed in control, non-infected cells;
however, when higher virus titre is used (9 lL of Lenti-uPA),
a residual but signiﬁcant uPA transcript level was observed
(ratio 4.3), because the expression blockade by 30 ng/mL
doxycycline was not complete under these conditions,
because of a slight leakiness of the cytomegalovirus
(CMV) promoter. The same observations were made with
cells infected with Lenti-uPA-Mut, expressing the dominant-
negative, mutated form of uPA (Fig. 1d). Under these
conditions, lentivirus-mediated expression of CD81 tran-
scripts was also fully blocked by doxycycline, in agreement
with previous data (Bahi et al. 2004a, 2005b) whereas b-
actin levels was not affected (Figs 1b and d).
The effects of the three silencing lentiviruses, that express
different siRNAs (targeting bp 21–45, 1270–1293 and 673–
692 of the mRNA of uPA and uPA-mut) were tested in
HEK293T cells co-infected with 3 lL of either Lenti-uPA
(Fig. 2a) or Lenti-uPA-mut (Fig. 2b), together with Lenti-
siRNAs (either Lenti-uPA-Sil1, Lenti-uPA-Sil2, Lenti-uPA-
Sil3 or all together). These silencing lentivirus constructs are
not doxycycline-regulated. Target speciﬁcity was controlled
by co-infections of HEK293T cells with Lenti-CD81 (Bahi
Fig. 1 Changes in urokinase plasminogen activator (uPA) mRNA
expression after cell infection. HEK293T cells were infected with 0 lL
(control), 3, 6 or 9 lL of Lenti-uPA (a, b) or Lenti-uPA-Mut (c, d),
together with 3 lL of Lenti-CD81. Cells were maintained in standard
Dulbecco’s modiﬁed Eagle’s medium (DMEM; a, c) or in DMEM sup-
plemented with 30 ng/mL of doxycycline (b, d). Total RNA was
extracted, reverse transcribed and used for quantitative real-time PCR
using speciﬁc primers. Values indicate means ± SEM. PCR products
were loaded on 2% agarose gel. *p < 0.05 compared with doxycy-
cline-treated cells; p < 0.05, p < 0.01, p < 0.005 compared with
control cells; p < 0.05, p < 0.01, p < 0.005 compared with
doxycycline-free DMEM cultured cells.
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et al. 2004b, 2005b). Cells were harvested 96 h after
infection, total RNA was extracted and transcripts levels
were measured by means of quantitative RT-PCR using
speciﬁc primers for each candidate. All normalizations were
performed against GAPDH. qRT-PCR showed 85, 26 and
76% reduction of uPA mRNA in cells co-infected with Lenti-
uPA, under these conditions (Fig. 2a), and 81, 45 and 73%
reduction of uPA-Mut mRNA in cells co-infected with Lenti-
uPA-Mut (Fig. 2b). When cells were co-infected with all
three Lenti-siRNAs simultaneously (Lenti-uPA-Sil1, Lenti-
uPA-Sil2 and Lenti-uPA-Sil3), almost 92% reduction of uPA
or of uPA-Mut mRNA was observed. Lenti-siRNAs had no
effects on other mRNA targets, e.g. CD81 or b-actin used as
controls – under all conditions, the expression levels of
CD81 or b-actin mRNAs were not affected by Lenti-siRNAs
infection, indicating that these targets are highly uPA-
speciﬁc. The expression levels of control genes were 56
and 45%.
In vivo uPA silencing
Six groups of lentivirus-infected animals (n ¼ 9 each) were
used for assessing the levels of uPA expression in the VTA,
as measured by qRT-PCR (Figs 3a and b). First, behavioural
evaluation was performed in three 5-day sessions: session A
(no doxycycline, full gene expression), session B (animals
fed doxycycline, inducing local gene suppression) and then
session C (no doxycycline, recapitulating both gene expres-
sion of session A and initially observed behaviour). Chronic
cocaine administration was continued daily throughout each
session A, B and C. This protocol enables for behavioural
evaluation of effects of local gene expression changes on the
very same animals (Bahi et al. 2004a,b, 2005a,b).
When animals were injected with Lenti-uPA in the VTA,
cocaine induced strong expression of uPA transcripts in
doxycycline-free, with a ratio of 12.5 (session A) and 11.7-
fold (session C), but only 3.6 in the presence of doxycycline
(session B), when normalized against GAPDH. Under these
conditions, the ratios of expression levels for CD81 or
b-actin were 3.0 and 1.0, respectively, and remained
unchanged by switch of regimen. Evaluation of CD81
expression was used as a control, as it is well established that
CD81 is endogenously induced in this brain area upon
chronic cocaine under the same conditions (Bahi et al.
2004a, 2005a). In full agreement with the present data, we
Fig. 2 Quantitative real-time PCR of uPA expression in HEK293T
cells transfected with Lenti-uPA-siRNA. HEK293T cells were infected
with 3 lL of Lenti-uPA (a) or Lenti-uPA-Mut (b), together with 3 lL of
Lenti-CD81 (as control) with or without Lenti-uPA-siRNAs. Total RNA
was extracted, reverse transcribed and used for real-time PCR using
speciﬁc primers. Values indicate means ± SEM. PCR products were
loaded on 2% agarose gel. Control, 3 lL of Lenti-uPA or Lenti-uPA-
Mut + 3 lL of Lenti-CD81; T1, 3 lL of Lenti-uPA or Lenti-uPA-
Mut + 3 lL of Lenti-CD81+ 3 lL of Lenti-uPA-Sil1; T2, 3 lL of Lenti-
uPA or Lenti-uPA-Mut + 3 lL of Lenti-CD81+ 3 lL of Lenti-uPA-Sil2;
T3, 3 lL of Lenti-uPA or Lenti-uPA-Mut + 3 lL of Lenti-CD81+ 3 lL of
Lenti-uPA-Sil3; All, 3 lL of Lenti-uPA or Lenti-uPA-Mut + 3 lL of
Lenti-CD81+ 3 lL of the three targets of Lenti-uPA-Sil. *p < 0.05,
**p < 0.005, ***p < 0.001 compared with control cells.
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previously reported that chronic cocaine delivery induces
uPA (10.5-fold; Bahi et al. 2004b) and CD81 (3.2-fold;
Bahi et al. 2004a) into the VTA. Furthermore, we observed a
10.1-fold endogenous expression of uPAR in this brain area.
When animals are fed doxycycline in session B, down-
regulation of uPA is accompanied by a similar down-
regulation of uPAR to 2.9-fold, that is fully reversed later in
session C, when animals are again fed without doxycycline.
This effect was not observed for PAI-1, whose expression
remained relatively constant under all conditions and seemed
not affected by the levels of uPA expression.
When animals were infected with Lenti-uPA-Mut, expres-
sing a dominant-negative form of uPA in the VTA, the
expression ratios were almost similar to the previous group in
all sessions (p > 0.21, session C vs. session A). Surprisingly,
expression of the dominant-negative uPA-Mut also induces a
9- and 11.8-fold uPAR expression (not PAI-1), as observed in
both sessions A and C, respectively, but not in session B,
when uPA-Mut is not expressed.
When animals, infected either with Lenti-uPA or with
Lenti-uPA-Mut, were co-infected with a mix of Lenti-uPA-
siRNAs, drastic inhibition of uPA and, respectively, uPA-
Mut expression, was observed in session A, resulting in a
ratio of 2.1 in both groups, i.e. a 6-fold inhibition
(p < 0.01 vs. Lenti-uPA- or Lenti-uPA-Mut-infected ani-
mals, respectively). Lenti-uPA-siRNAs had no signiﬁcant
effects on b-actin and CD81 expression (p > 0.25 vs. Lenti-
uPA- or Lenti-uPA-Mut-infected animals). In session B, uPA
or uPA-Mut expression are strongly inhibited, with ratios
0.7 (p < 0.005 vs. Lenti-uPA- or Lenti-uPA-Mut-infected
Fig. 3 Quantitative real-time PCR of uPA, uPA receptor (uPA-R) and
uPA inhibitor (uPA-I) expression in vivo. Six groups of rats (n ¼ 9)
were stereotaxically injected into the VTA with 4 lL lentiviral vector
mix (at 2 to 105 ng/mL p24 each lentivirus). After recovery, animals
were chronically injected with cocaine (daily injection of 15 mg/kg i.p.)
under a different regimen and locomotor activity was measured daily.
Session A: animals were fed with normal water over 5 days; ses-
sion B: the same animals were then switched to the doxycycline
regimen for a further 5 days; session C: ﬁnally the same animals were
re-switched again to a normal doxycycline-free regimen for a further
5 days. Chronic cocaine administration was continued daily through-
out each of sessions A, B and C. At the end of each session, three
animals were killed by decapitation, brains were removed and various
regions including the VTA were dissected out. Total RNA was
extracted, reverse transcribed and used for quantitative PCR using
speciﬁc primers. (a) Quantitative mRNA levels normalized against
GAPDH. (b) PCR products were loaded on 2% agarose gel uPA:
Lenti-uPA alone; uPA-Mut: Lenti-uPA-Mut alone; uPA-Sil: Lenti-
uPA + Mix of Lenti-uPA-Sil; uPA-Mut + Sil: Lenti-uPA-Mut + Mix of
Lenti-uPA-Sil; GFP-Sil: Lenti-GFP + Mix of Lenti-uPA-Sil: GFP: Lenti-
GFP alone. *p < 0.05, **p < 0.01 compared with uPA group;
p < 0.05, p < 0.01 compared with uPA-Mut group; p < 0.05
compared with GFP group; p < 0.05, p < 0.01 compared with
doxycycline-free water-fed animals (sessions A and C). §p < 0.05,
§§p < 0.01, §§§p < 0.001 compared with uPA-R expression.
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animals). Doxycycline blocks exogenous, lentiviral-mediated
uPA or uPA-Mut over-expression, but not the endogenously
expressed uPA, while the silencers also block endogenous
uPA. Under these conditions, the other targets, CD81 or
b-actin, were not modiﬁed at all (p > 0.25 vs. Lenti-uPA-
infected animals). Removal of doxycycline in session C
restores the levels back to those observed during session A.
Interestingly, suppression of uPA or uPA-Mut expression by
the siRNAs expressing lentiviruses also results in strong
down-regulation of uPAR (respectively, 2.4- and 2.7-fold
expression in session A, 0.5- and 0.4-fold expression in
session B and, again, 2.5- and 2.3-fold expression in
session C).
A group of animals was infected with Lenti-GFP only (a
mock control, to evaluate endogenous uPA expression), and a
last group was injected Lenti-GFP together with Lenti-uPA-
siRNAs mix (for silencing of endogenous uPA). When
infected with Lenti-GFP only, uPA expression was 3.9 in
session A, reﬂecting cocaine-mediated induction of endo-
genous uPA by chronic cocaine, in full accordance with our
previous ﬁnding (Bahi et al. 2004b). When Lenti-uPA-
siRNAs were co-infected with Lenti-GFP, uPA mRNA
expression level was only 0.5 in session A, indicating that
a 90% knock down of the endogenous uPA had been
achieved with a mix of Lenti-uPA-siRNAs (p < 0.05 vs.
Lenti-GFP-infected animals). In this same group, b-actin and
CD81 mRNAs were unchanged. In session B, the ratios
remained unchanged in Lenti-GFP-treated animals (p > 0.23
vs. Lenti-GFP-infected animals in session A). Animals
treated with Lenti-GFP and Lenti-uPA-siRNAs also dis-
played lower uPA expression in session B, with a ratio 0.5
(p < 0.01 vs. Lenti-GFP-infected animals), whereas other
targets, e.g. b-actin and CD81, were not modiﬁed (p > 0.25
vs. Lenti-uPA-infected animals). Removal of doxycycline (in
session C) restored uPA levels back to those observed during
session A (p > 0.23 session A vs. session C) in both groups
(4.1- vs. 0.6-fold, p < 0.05), but control genes remained
unmodiﬁed (a 1.2- and 3.0-fold increase for b-actin and
CD81, respectively, in agreement with previous observations,
Bahi et al. 2004a,b, 2005a,b) and an increase of uPAR was
observed in animals treated with Lenti-GFP only.
Behavioural changes induced upon uPA expression
Animals infected with only Lenti-GFP served as a control
group expressing GFP in the VTA in a doxycycline-regulated
way. After surgery, animals were fed water, enabling full
expression of GFP in the target area. One week after surgery,
chronic drug delivery was started and locomotor activity was
monitored. At each daily session, animals received saline
injections before the habituation period (30 min) followed by
cocaine delivery (i.p. 15 mg/kg) and the locomotor activity
was monitored over 60 min immediately after drug injection.
During session A, saline injection induced low levels of
locomotor activity (46 counts), while cocaine delivery
produced a signiﬁcant induction of locomotor activity
(241 counts; means over a 5-day session). But no signi-
ﬁcant changes were observed when the animals were
changed regimen (i.e. fed doxycycline after 5 days, ses-
sion B, or fed back without doxycycline after 10 days,
session C). Also, no signiﬁcant behavioural sensitization was
observed under these conditions (Fig. 4b).
Animals infected with doxycycline-regulatable Lenti-uPA
into the VTA underwent similar treatment. Saline delivery
before the habituation period induced locomotor activity
comparable with the GFP control group under all doxy-
cycline regimens (47 counts, p > 0.2 sessions A and C vs.
session B). But after cocaine injection, a phenomenal
increase in locomotor activity was observed in session A,
with a total activity of 1442 counts. After 5 days, the
regimen was switched and the very same animals (n ¼ 6)
were fed doxycycline in the drinking water (inducing down-
regulation of exogenous, lentivirus-induced expression of
uPA in the VTA), and their behaviour upon chronic cocaine
treatment was further monitored daily for ﬁve consecutive
days (session B) – under these conditions, the distance
travelled during the habituation period was unchanged
(average 50 counts, p > 0.2 vs. Lenti-uPA of session A),
whereas after cocaine injection a total distance dropped down
to 367 counts. After 5 days under this regimen, doxy-
cycline was removed (session C, enabling re-expression of
lentivirus-mediated uPA in the VTA). Under these condi-
tions, no changes were observed during the habituation
period (52 counts, p > 0.2 vs. Lenti-uPA of sessions A and
B), but after cocaine injection locomotor activity returned
back to its initial levels (1640 counts). The difference
between sessions A and C was not signiﬁcant (p > 0.2). Note
the very strong and signiﬁcant sensitization observed during
session A, but no more during sessions B and C (Fig. 4b).
To check the direct uPA inhibition, a separate group of
animals was administered B428, an uPA inhibitor, in the
drinking water and locomotor activity was measured
(Fig. 4c). In presence of B428, complete inhibition of uPA
had been described (Towle et al. 1993; Todaro et al. 2003).
Under these conditions, locomotor activity was completely
blocked during the habituation period and negligibly
increased after cocaine administration (10 counts). This
compound, however, appears to act as an anaesthetic rather
than a true inhibitor of uPA over-expression in this brain
region.
Animals injected with Lenti-uPA-Mut, the lentivirus
expressing the mutated, dominant-negative form of uPA,
display a small but signiﬁcant inhibition in cocaine-mediated
locomotor activity when compared with GFP control groups.
The mutated form of uPA is interfering with the endogenous
expressed one (Bahi et al. 2004b). Note also the absence of
signiﬁcant behavioural sensitization in this group (Fig. 4b).
Animals (n ¼ 9) co-injected with the regulatable Lenti-
uPA (same concentration as the ﬁrst group) together with
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(non-regulatable) Lenti-uPA-siRNAs were submitted to the
same regimen and drug treatments. In session A, i.e. when
lentivirus-mediated uPA expression is silenced by the Lenti-
siRNAs, cocaine delivery induces low locomotor activity
(310 counts), corresponding to a 4.6-fold decrease of the
activity monitored under the same conditions in the absence
of siRNAs (p < 0.05 vs. Lenti-uPA). After 5 days, doxycy-
cline was added to the regimen (session B), inducing down-
regulation of exogenous, lentivirus-mediated uPA expression
(but not of lentivirus-siRNAs). Under these conditions, upon
cocaine injection a total travelled distance of 207 counts
was observed, signiﬁcantly lower than in session A and
Fig. 4 Cocaine-mediated hyperlocomotion
is blocked by silencing uPA expression in
the VTA. Daily locomotor activity of animal
groups used for Fig. 3. uPA expression in
the VTA was silenced locally by bilateral
stereotaxic injection of Lenti-uPA-siRNAs
as described in Fig. 3. (a) Total mobility
counts averaged over each 5-day period. In
all sessions, rats were treated with saline
(1 mL/kg i.p.), and the locomotor activity
was measured for 30 min (habituation per-
iod). Rats then received an i.p. injection of
15 mg/kg of cocaine and locomotor activity
was assessed for a further 60 min. Initially
animals were fed doxycycline-free water for
5 days (session A, –Doxy). Animals were
then switched to the doxycycline regimen
for a further 5 days (session B, +Doxy).
Finally, animals were switched back to a
normal, doxycycline-free regimen (ses-
sion C, –Doxy). Chronic cocaine adminis-
tration was continued daily throughout each
of sessions A, B and C. (b) Differential
habituation and sensitization over the three
sessions. Daily data from (a) are plotted
individually for each group separately. (c)
Animals injected with Lenti-uPA into the
VTA were injected with B428 (30 mg/kg,
i.p.). Thirty minutes later rats were injected
with saline (1 mL/kg, i.p.) and placed in
testing cages for half an hour. After this
period, animals received cocaine (15 mg/
kg) and were then placed back into the
locomotor activity-monitoring cage for
60 min. *p < 0.001 compared with the uPA
group; p < 0.05 compared with the uPA-
Mut group; p < 0.05 compared with the
GFP group; §p < 0.05, §§p < 0.001 com-
pared with doxycycline-fed animals;
¶p < 0.05, ¶¶p < 0.01, ¶¶¶p < 0.001 com-
pared with cocaine-treated animals;
ap < 0.01, aap < 0.0001 compared with
B428-treated animals.
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similar to GFP-treated animals under corresponding condi-
tions (p < 0.05 vs. sessions A and C). When doxycycline
was ﬁnally removed from the water on the very same animals
(session C), enabling full expression of the Lenti-uPA in the
VTA, the locomotor activity raised back to the level observed
in session A (361 counts after cocaine delivery, p > 0.22
vs. session A). No signiﬁcant behavioural sensitization was
observed in this group of animals where uPA had been
silenced by siRNAs in all three sessions (Fig. 4b).
Very similar results were found with the group of animals
co-infected with Lenti-uPA-Mut and with Lenti-uPA-siRNAs
(Figs 4a and b).
Finally, animals co-infected with Lenti-GFP and Lenti-
uPA-siRNAs served to assess effects of endogenous uPA. In
the absence of doxycycline (session A), animals displayed
the same locomotor activity during the habituation period
(48 counts, p > 0.2 vs. Lenti-uPA), but a high locomotor
activity after cocaine delivery (138 counts, p < 0.05 vs.
Lenti-GFP). When switched to the doxycycline regimen,
either in session B or later in session C, no signiﬁcant
changes were observed (p > 0.2).
At the end of each session, expression of uPAwas assessed
by means of immunocytochemistry on the brain section from
one of the animals which had been killed. As displayed in
Fig. 5, doxycycline treatment, as well as treatment with
Lenti-uPA-siRNAs, results in > 95% decrease in uPA-
positive cells in the targeted area.
Discussion
uPA is strongly over-expressed after cocaine delivery under
various paradigms (chronic, acute or binge) and strongly
affects locomotor behaviour (Bahi et al. 2004b). The present
study ﬁrmly establishes these data and yields a 15-fold
change in locomotor activity upon cocaine delivery (com-
pared with saline injection). This considerable change is very
selective and may be systematically manipulated through
doxycycline, in full agreement with our previous study. This
study points to an important role of the plasmin system in
chronic cocaine. Other studies showed already that the tPA-
plasmin system releases dopamine in the NAc upon meth-
amphetamine, which activates long-term synaptic plasticity
and remodelling, and acutely participates in the rewarding
effects of methamphetamine or morphine (Ripley et al. 1999;
Iwata et al. 2004; Nagai et al. 2004; Yamada et al. 2005).
Activity-dependent synaptic plasticity and remodelling of the
mesolimbic dopaminergic system play a crucial role in the
development of drug dependence (Koob et al. 1998; Nestler
2001).
Plasminogen activators, tPA and uPA, both convert
plasminogen to plasmin (Vassalli et al. 1991), which in turn
function to degrade extracellular matrix (ECM) components
(Werb 1997; Flumelli et al. 1999). Its involvement in the
ﬁbrinolysis of the blood clot is well known, but a large body
of evidence has shown that this system also functions in the
CNS. Synaptic reorganization takes place continuously as
neurons undergo stimulation and requires remodelling of
ECM through the action of extracellular proteases, including
plasminogen activators (Tsirka et al. 1995, 1997; Werb 1997;
Tsirka 2002). Plasmin plays an important role in neurite
extension and synaptic remodelling by altering the cell–ECM
interaction (McGuire and Seeds 1990). The role of uPA, for
dendritic spine dynamics regulated by ECM degradation, is
well established (Fiorillo et al. 1998; Oray et al. 2004).
Fig. 5 Immunocytochemistry of uPA
expression in the VTA. (a) Animals injected
with Lenti-uPA, after session A; (b) animals
injected with Lenti-uPA and Lenti-silencers;
(c) animals injected with Lenti-uPA, as in
(a), fed doxycycline (after session b); (d)
animals injected with Lenti-uPA and Lenti-
silencers, as in (b), fed doxycycline (after
session B). Chronic cocaine administration
was continued daily throughout each of
sessions A and B. See Experimental pro-
cedures. Magniﬁcation 10 ·, inserts 40 x.
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Plasmin degrades several ECM proteins, including laminin
(Goldﬁnger et al. 2000), which localizes calcium channels to
the sites of active zones in the synaptic cleft (Bixby et al.
1994; Sunderland et al. 2000). Therefore, a uPA- or tPA-
mediated modulation of plasminogen activation may result in
a malfunction of calcium channel activity and leads to the
reduction of depolarization-evoked dopamine release in
dopaminergic neurons (Nagai et al. 2004).
Furthermore, our investigation gives evidence that local
over-expression of uPA in the VTA induces endogenous
expression of its receptor uPAR, but not its inhibitor PAI-1.
Both uPAR expression and cocaine-induced behavioural
changes are regulated upon uPA silencing. uPAR is highly
up-regulated in the presence of uPA, but also when the
dominant-negative uPA mutant is expressed, in agreement
with the well-established fact that signalling functions of uPA
do not require its proteolytic activity (Tarui et al. 2003). uPA
is secreted as an inactive pro-enzyme, which, after binding to
its cell surface high-afﬁnity receptor, is rapidly activated to
active uPA by plasmin. By uPA binding to uPAR, it can
localize enzyme activity at the cell surface and contact other
molecules on the cell surface and in the extracellular matrix
(de Bock and Wang 2004). The mechanisms of cocaine-
mediated uPAR expression remain to be established. Cocaine
activates several pathways, among them redox-sensitive
transcription factors, e.g. nuclear factor-kappa-B (NF-jB),
activator protein-1 (AP-1), and TNF-a gene expression (Ang
et al. 2001). NF-jB in turns activates uPAR transcription,
binding to its promoter region at position )45, and AP-1
presents binding motifs located at )184 bp of the uPAR
promoter (Wang et al. 2000). uPAR in turn appears to be
ﬁnely tuned in various environments by complex mecha-
nisms controlling its gene expression. uPAR mRNA is highly
inducible and unstable, but it is strongly stabilized by
interaction with the integrin LFA-1 (CD11a/CD18), which
has a major stabilizing effect on the 3¢ UTR of uPAR mRNA
(Wang et al. 1998), enhancing uPAR mRNA half-life and its
engagement into cell adhesion integrin-mediated cascade.
Integrins, through interactions with matrix ligands, inﬂuence
gene expression largely through kinase cascades modulating
transcription factor complexes, which synergize with growth
factor responses and also lead to increased synaptic plasticity,
as observed upon cocaine sensitization. However, at least
two forms of uPAR have been described, which engage
different signalling cascades and multiple interactions with
G protein-coupled receptors (Mazzieri et al. 2005).
In view of the facts that uPAR is highly up-regulated in the
presence of both uPA, or its dominant-negative mutant form,
that both forms bind the receptor, and that no proteolytic
activity is needed for the cellular signalling, why are the
observed phenotypes then so different? In our studies, only
the active form of uPA induces signiﬁcant cocaine-mediated
behavioural changes, which probably implies that plasmin
activation plays a signiﬁcant role in this process. This is
supported by the full behavioural inhibition observed after
cocaine in the presence of B428, an uPA inhibitor.
In certain tumour and stromal cells, uPA activity may be
neutralized and regulated by PAI-1. Models of self-regulation
of the uPA-uPAR-PAI-1 system have been proposed
(reviewed by de Bock and Wang 2004). Interestingly, this
type of mechanism seems not to occur in the cocaine
paradigms under investigation in our study. No changes in
PAI-1 expression were observed under any circumstance,
despite reports that cocaine administration may be associated
with an increase in plasma PAI-1 activity, which may play a
role in vascular thrombosis by recreational users of the drug
(Moliterno et al. 1994).
Plasmin regulates a cascade of extracellular proteolytic
activities involved in neurite outgrowth, cell migration
(Moonen et al. 1982; Seeds et al. 1999), long-term poten-
tiation and depression (Frey et al. 1996; Calabresi et al.
2000), learning and memory (Madani et al. 1999; Calabresi
et al. 2000), excitotoxic cell death (Tsirka et al. 1997; Nicole
et al. 2001), and regeneration or recovery from injury in the
nervous system (Siconolﬁ and Seeds 2001; Wolfer et al.
2001). These ﬁndings suggest that plasmin is involved in the
regulation of numerous aspects of synaptic plasticity and
remodelling (Shimizu et al. 1998). tPA and uPA are
synthesized in most brain regions (Sappino et al. 1993;
Salle and Strickland 2002) and their localized expression
during neuronal development suggests that plasmin-mediated
proteolysis facilitates neurite outgrowth and cell migration
(Sumi et al. 1992; Ware et al. 1995).
In addition, tPA is induced as an immediate-early gene
accompanying seizure, kindling, or LTP, and contributes to
structural changes observed during activity-dependent syn-
aptic plasticity (Pang et al. 2004; Pawlak et al. 2005). tPA-
deﬁcient mice are resistant to excitotoxin-induced neuronal
degeneration in the hippocampus and have an elevated
threshold for seizure (Tsirka et al. 1995; Tsirka et al. 1997)
and a reduction in the maintenance of LTP (Frey et al. 1996).
In contrast, mice over-expressing tPA show an enhanced LTP
(Madani et al. 1999), whereas mice over-expressing uPA
display impaired learning (Meiri et al. 1994). In organotypic
hippocampal cultures, the maintenance of LTP is impaired by
degradation of laminin, indicating that laminin-mediated
cell–ECM interaction may be necessary for the maintenance
of LTP (Nakagami et al. 1997, 2000). Together, these data
show that plasmin promotes synaptic plasticity as an acute
effect.
However, uPA may also regulate synaptic plasticity
through mechanisms independent of plasmin or laminin, in
analogy to mechanisms proposed for tPA, such as mediating
an interaction between microglia and dopaminergic neurons
(Nakajima et al. 1994). Microglia activated by secreted tPA
affect mossy ﬁbre pathﬁnding and outgrowth and other
proteases released by microglia and then promote neurite
growth (Bednarski et al. 1997; Patton et al. 1998; Wu et al.
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2000). It may also induce a plasminogen-independent
mechanism (Tsirka et al. 1997) or activate other substrates,
such as hepatocyte growth factor (Powell et al. 2001), or yet
another physiological target of plasmin, e.g. DSD-1-PG/
phosphacan, an extracellular matrix component associated
with neurite reorganization (Wu et al. 2000). Plasminogen-
deﬁcient mice exhibit DSD-1-PG/phosphacan deposition, as
tPA functions acutely, both through and independently of
plasmin, to mediate mossy ﬁbre reorganization and remod-
elling of neuronal connections, a mechanism implicated in
seizure episodes (Wu et al. 2000). Seizure in addicts is very
common and, from our present data, may well involve uPA-
mediated plasminogen activation. More studies will be
required to clarify these different possible pathways and
the role of uPA and uPAR in response to cocaine.
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